Article Text

PDF
▼Tocilizumab for rheumatoid arthritis

Abstract

▼Tocilizumab (RoActemra – Roche) is a new biological agent available in the UK for the treatment of adults with rheumatoid arthritis.1 Unlike currently available biological agents, the drug targets the pro-inflammatory cytokine interleukin-6 (IL-6). Here, we consider the place of tocilizumab in rheumatoid arthritis and whether it offers any advantages over other biological agents.

Statistics from Altmetric.com

Footnotes

  • * For an explanation on non-inferiority trials, please see DTB 2008; 46: 55–6.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.